BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Treatment
661 results:

  • 1. Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in prostate cancer.
    Hu C; Qiao X; Huang R; Hu C; Bao J; Wang X
    Radiol Imaging Cancer; 2024 May; 6(3):e230143. PubMed ID: 38758079
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A bicentric retrospective study of the correlation of EAU bcr risk groups with
    Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
    Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
    Lee LJ; Han CJ; Saligan L; Wallen GR
    Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy.
    Checcucci E; De Cillis S; Alladio E; Piramide F; Volpi G; Granato S; Zamengo D; Bignante G; Amparore D; Piana A; Manfredi M; Vallariello E; Stura I; Di Dio M; Autorino R; Porpiglia F; Fiori C
    Prostate; 2024 Jun; 84(9):832-841. PubMed ID: 38572570
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
    Yamada Y; Fujii Y; Kakutani S; Kimura N; Sugimoto K; Hakozaki Y; Sugihara T; Takeshima Y; Kawai T; Nakamura M; Kamei J; Taguchi S; Akiyama Y; Sato Y; Yamada D; Urabe F; Miyazaki H; Enomoto Y; Fukuhara H; Nakagawa T; Fujimura T; Kume H
    Sci Rep; 2024 Mar; 14(1):7607. PubMed ID: 38556562
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
    Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
    World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
    Fletcher SA; Mamawala MM; Holler AE; Bhanji Y; Macura KJ; de la Calle CM; Pavlovich CP
    Prostate; 2024 Jun; 84(8):723-730. PubMed ID: 38476030
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
    Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
    Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
    Teppala S; Scuffham PA; Tuffaha H
    Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical prostatectomy.
    Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
    J Urol; 2024 Apr; 211(4):509-517. PubMed ID: 38421253
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
    J Urol; 2024 Apr; 211(4):526-532. PubMed ID: 38421252
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part II: treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical prostatectomy.
    Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
    J Urol; 2024 Apr; 211(4):518-525. PubMed ID: 38421243
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Yin W; Chen G; Li Y; Li R; Jia Z; Zhong C; Wang S; Mao X; Cai Z; Deng J; Zhong W; Pan B; Lu J
    Cancer Lett; 2024 Apr; 588():216739. PubMed ID: 38395379
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer.
    Koguchi D; Tsumura H; Tabata KI; Shimura S; Satoh T; Ikeda M; Watanabe A; Yoshida T; Sasaki J; Matsumoto K; Iwamura M
    Jpn J Clin Oncol; 2024 May; 54(5):569-576. PubMed ID: 38305663
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
    Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
    Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
    Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
    Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
    Sweeney C; Gilsenan A; Calingaert B; Moeller C; Schomakers G; Sok A; Holzmann R; Pisa F
    Pharmaceut Med; 2024 Mar; 38(2):145-156. PubMed ID: 38296916
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.
    Watanabe K; Kamitani N; Ikeda N; Kawata Y; Tokiya R; Hayashi T; Miyaji Y; Tamada T; Katsui K
    Brachytherapy; 2024; 23(2):179-187. PubMed ID: 38245406
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
    Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
    J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 34.